RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois
23 janv. 2023 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81
06 déc. 2021 08h45 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury
29 nov. 2021 08h45 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
22 avr. 2021 08h45 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
08 févr. 2021 21h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the...
RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split
08 févr. 2021 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the...
RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split
05 janv. 2021 16h05 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has, on January 4, 2021, filed with the Secretary of State of...
RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows
27 oct. 2020 08h55 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury
06 oct. 2020 09h00 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development
25 sept. 2020 09h10 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...